₹642.00
−1.39%NSE close, 16 Nov 2026
+36.23%
Nephrocare Health Services is a small cap company in the Healthcare sector, listed on NSE under the symbol NEPHROPLUS. At ₹642.00 a share, the market values the whole company at ₹6,456 crore.
In FY26, it reported sales of ₹999 crore and a net profit of ₹77 crore, an operating margin of 22.7%.
The market values the company at 50.4 times its profit over the last twelve months and 5.43 times its book value; its return on equity is 10.8% and its borrowings are 0.07 times its equity.
Promoters hold 58.31% of the shares. Foreign institutions hold 11.73%, and domestic institutions, mutual funds among them, 8.11%.
Companies of a similar size in the same sector include Strides Pharma Science, Aarti Pharmalabs, Healthcare Global Enterprises and Thyrocare Technologies.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Nephrocare Health Services | ₹642.00 | ₹6,456 cr | 50.4 | 10.8% | n/a | n/a |
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 |
Transcript
Schedule of meet
Link of Recording
Pursuant to Reg 32 of SEBI LODR Regulations, 2015 read with Reg 41 of SEBI ICDR Regulations, 2018, please find enclosed Monitoring Agency Report for the quarter ended September 30, 2026.
| 20.2% |
| 22.7% |
| 22.1% |
| Other income | 3.3 | 11.6 | 7.5 | 8.0 |
|---|
| Interest | 6.0 | 3.2 | 2.2 | 3.1 |
|---|
| Depreciation | 21.9 | 25.9 | 24.5 | 27.7 |
|---|
| Profit before tax | 36.4 | 36.3 | 44.6 | 44.3 |
|---|
| Tax | 4.1 | 2.9 | 9.1 | 6.9 |
|---|
| Net profit | 32.2 | 30.4 | 32.0 | 33.5 |
|---|
| EPS (₹) | 3.43 | 3.03 | 3.19 | 3.34 |
|---|
₹ crore, financial years to March.
| Line | FY26 |
|---|---|
| Sales | 999 |
| Expenses | 772 |
| Operating profit | 227 |
| Operating margin | 22.7% |
| Other income | 24.5 |
| Interest | 60.2 |
| Depreciation | 90.7 |
| Profit before tax | 101 |
| Tax | 20.6 |
| Net profit | 76.8 |
| EPS (₹) | 8.48 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY26 | 6M to Sep 2026 |
|---|---|---|
| From operations | 233 | 89.4 |
| From investing | −410 | −24.7 |
| From financing | 157 | 22.4 |
| Spent on fixed assets | −119 | −37.2 |
| Free cash flow | 114 | 52.3 |
Margins, returns, debt, tax and cash.
| Line | FY26 |
|---|---|
| Net margin | 7.7% |
| Operating margin | 22.7% |
| Return on equity | 6.9% |
| Return on capital employed | 13.4% |
| Return on assets | 5.2% |
| Debt to equity | 0.07 |
| Interest coverage | 2.70 |
| Debt to assets | 0.05 |
| Current ratio | 2.80 |
| Quick ratio | 2.69 |
| Cash ratio | 0.41 |
| Asset turnover | 0.68 |
| Fixed asset turnover | 2.52 |
| Inventory turnover | 6.90 |
| Receivables turnover | 3.20 |
| Gross margin | 77.3% |
| Cash from operations to profit | 303.0% |
| Effective tax rate | 20.5% |
| 26.1% |
| +25.10% |
| +15.46% |
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a | -84.2% | +30.40% | +39.45% |
|---|
| Sun Pharma Advanced Research Company | ₹195.84 | ₹6,355 cr | 3.9 | 113.4% | +282.10% | +45.52% |
|---|
| Senores Pharmaceuticals | ₹1,147.80 | ₹5,286 cr | 38.2 | 13.8% | +18.90% | +42.61% |
|---|
| Supriya Lifescience | ₹622.30 | ₹5,008 cr | 28.3 | 14.3% | +3.20% | −20.15% |
|---|
Nephrocare Health Services Limited, Asia s largest dialysisnetwork under the brand NephroPlus announced its Financial Results for second quarterand half year ended 30th September 2026
The financial results for the period ended September 30, 2026.
Schedule of meet
Other Restructuring - Rationalisation and Consolidation of Company''s Step-down Subsidiaries in the Philippines as per the disclosure annexed herewith.
Grant of Employee Stock Options under the NephroPlus Employee Stock Option Scheme 2026.
Acquisition of 100% participatory interest in Dialysis Center Almaty LLP, Kazakhstan